Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516--The Southwest Oncology Group Export

@article{citeulike:3884395, abstract = {PurposeTo investigate the incidence, natural history, and risk factors predictive of CNS relapse in patients with de novo aggressive lymphomas and to evaluate the efficacy of CNS prophylaxis in patients with initial bone marrow (BM) involvement. Patients and MethodsWe conducted an analysis of CNS events from 20-year follow-up data on 899 eligible patients with aggressive lymphoma treated on Southwest Oncology Group protocol 8516, a randomized trial of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin), ProMACE (prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide)-CytaBOM (cytarabine, bleomycin, vincristine, methotrexate), and m-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide). Patients with BM involvement randomly assigned to receive ProMACE-CytaBOM (63 patients) or m-BACOD (58 patients) were to receive CNS prophylaxis, whereas those randomly assigned to receive CHOP or MACOP-B did not. ResultsCNS relapse is uncommon (25 of 899 patients), with a cumulative incidence of 2.8\%. CNS relapse occurs early (median time to relapse, 5.4 months from diagnosis). Indeed, 20 of 25 patients with CNS relapse relapsed during chemotherapy, or within 6 months of completion. The number of extranodal sites and the International Prognostic Index were predictive of CNS relapse. There was no significant benefit of CNS prophylaxis in patients with BM involvement at diagnosis; however, given the small number of events, the power of this analysis is limited. ConclusionThe early occurrence of CNS events suggests that these patients had subclinical disease at initial diagnosis. As such, strategies to better detect and treat patients with subclinical CNS disease at diagnosis would be anticipated to result in a decrease in the incidence of CNS relapse, without subjecting those patients not destined for CNS relapse to unnecessary and potentially toxic prophylaxis strategies. 10.1200/JCO.2008.16.8021}, author = {Bernstein, Steven H. and Unger, Joseph M. and Leblanc, Michael and Friedberg, Jonathan and Miller, Thomas P. and Fisher, Richard I.}, citeulike-article-id = {3884395}, citeulike-linkout-0 = {http://dx.doi.org/10.1200/JCO.2008.16.8021}, citeulike-linkout-1 = {http://jco.ascopubs.org/cgi/content/abstract/27/1/114}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/19047289}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=19047289}, day = {1}, doi = {10.1200/JCO.2008.16.8021}, journal = {J Clin Oncol}, keywords = {lymphoma, neuro, nhl}, month = {January}, number = {1}, pages = {114--119}, posted-at = {2009-07-20 02:56:28}, priority = {2}, title = {Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516--The Southwest Oncology Group}, url = {http://dx.doi.org/10.1200/JCO.2008.16.8021}, volume = {27}, year = {2009} }

TY - JOUR ID - citeulike:3884395 L3 - citeulike-article-id:3884395 N2 - PurposeTo investigate the incidence, natural history, and risk factors predictive of CNS relapse in patients with de novo aggressive lymphomas and to evaluate the efficacy of CNS prophylaxis in patients with initial bone marrow (BM) involvement. Patients and MethodsWe conducted an analysis of CNS events from 20-year follow-up data on 899 eligible patients with aggressive lymphoma treated on Southwest Oncology Group protocol 8516, a randomized trial of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin), ProMACE (prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide)-CytaBOM (cytarabine, bleomycin, vincristine, methotrexate), and m-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide). Patients with BM involvement randomly assigned to receive ProMACE-CytaBOM (63 patients) or m-BACOD (58 patients) were to receive CNS prophylaxis, whereas those randomly assigned to receive CHOP or MACOP-B did not. ResultsCNS relapse is uncommon (25 of 899 patients), with a cumulative incidence of 2.8%. CNS relapse occurs early (median time to relapse, 5.4 months from diagnosis). Indeed, 20 of 25 patients with CNS relapse relapsed during chemotherapy, or within 6 months of completion. The number of extranodal sites and the International Prognostic Index were predictive of CNS relapse. There was no significant benefit of CNS prophylaxis in patients with BM involvement at diagnosis; however, given the small number of events, the power of this analysis is limited. ConclusionThe early occurrence of CNS events suggests that these patients had subclinical disease at initial diagnosis. As such, strategies to better detect and treat patients with subclinical CNS disease at diagnosis would be anticipated to result in a decrease in the incidence of CNS relapse, without subjecting those patients not destined for CNS relapse to unnecessary and potentially toxic prophylaxis strategies. 10.1200/JCO.2008.16.8021 IS - 1 JF - J Clin Oncol EP - 119 TI - Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516--The Southwest Oncology Group VL - 27 SP - 114 KW - lymphoma KW - neuro KW - nhl AU - Bernstein, Steven AU - Unger, Joseph AU - Leblanc, Michael AU - Friedberg, Jonathan AU - Miller, Thomas AU - Fisher, Richard PY - 2009/01/01/ UR - http://dx.doi.org/10.1200/JCO.2008.16.8021 ER -